Buchynskyi M., Oksenych V., Kamyshna I., Kamyshnyi O. Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study. // Viruses.- 2024. -16(1). -е112

Buchynskyi. M., Kamyshna I., Oksenych V., Zavidniuk N., Kamyshnyi A. The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence //Viruses.- 2023.-15(5).-е 1072.

Kamyshnyi A, Koval H, Kobevko O, Buchynskyi M, Oksenych V, Kainov D, Lyubomirskaya K, Kamyshna I, Potters G, Moshynets O. Therapeutic Effectiveness of Interferon-α2b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience // Int J Mol Sci.- 2023.- 7;24(8).-е6887. 

Buchynskyi M., Kamyshna I., Lyubomirskaya K., Moshynets O., Kobyliak N., Oksenych V., Kamyshnyi A.  Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis //  Frontiers in immunology.-2023.- 14.- 1069-894.

Buchynskyi M, Oksenych V, Kamyshna I, Vari SG, Kamyshnyi A. Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis. // Viruses (Basel).-2023.-15(8).-P1724.

Kamyshnyi A, Koval H, Kobevko O, Buchynskyi M, Oksenych V, Kainov D, Lyubomirskaya K, Kamyshna I, Potters G, Moshynets O. Therapeutic Effectiveness of Interferon-α2b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience. // Int J Mol Sci (Basel).-2023.-24(8).-P6887.